about
Calculated globulin (CG) as a screening test for antibody deficiency.Current state of screening for Down's syndrome.Current screening approaches for antibody deficiency.Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.The influence of maternal opiate use in pregnancy on second trimester biochemical markers for Down syndrome.Direct access midwifery booking for prenatal care and its role in Down syndrome screening.Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies.Nomograms to help inform women considering Down's syndrome screening.The biological variation of insulin resistance in polycystic ovarian syndrome.Maternal serum dimeric inhibin A in second-trimester Down's syndrome pregnanciesLow maternal serum oestriol and chorionic gonadotropin in the prediction of adverse pregnancy outcomeFull blood count and second-trimester markers of Down's syndromeBiochemical screening for Down syndrome: patients' perception of riskA randomised controlled trial of placental cord drainage to reduce feto-maternal transfusionThe effect of newly diagnosed hypothyroidism on serum sodium concentrations: a retrospective studyIncorrect use of ratios in commercial assay kit instructionsThe LH/FSH ratio has little use in diagnosing polycystic ovarian syndromeAntigliadin antibody testing for coeliac disease in children under 3 years of age is unhelpfulReduction in Down's syndrome screening acceptance is predominantly observed in women aged 25-35 yearsIntroduction of first trimester combined test increases uptake of Down's syndrome screeningClinical evaluation of the BioPlex 2200 Celiac IgA and IgG Kits - a novel multiplex screen incorporating an integral check for IgA deficiencyIncidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitisChallenges and opportunities from the revised international consensus on ANCA testingUsing calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project
P50
Q34065381-1CBE0DD6-232E-4F61-ABB0-BAB6BAF2B023Q34537359-4E423E8F-36C5-4560-9F79-715E0E3EEAC8Q38619317-63494E27-B2A5-4BC3-A49E-B6DCA1A1CA4EQ45145839-E3CC22C2-B16C-453B-8DDB-ECF8434452DCQ45986569-BF5CFD6B-1682-477C-8F0E-AF70B33572E5Q50186087-00B37CDB-3C5C-4BAF-B60E-65FEC717F630Q51645966-67DAA1FC-4957-41B3-B052-C3F27524EDC1Q52868813-C545E372-EF49-4892-9BE3-03668FA11461Q53974699-40768820-04C4-4659-983E-FDA3D474A3DBQ61847118-D689C9E2-016B-4E16-BB80-BE3A80AD7B49Q70747442-3FA4F05D-0166-4ABB-AD91-9A6FC7BB52BAQ70967827-B67323E6-FF4E-4B49-A3E6-819BC7B912F0Q73502646-B659D4B1-5711-4712-881F-23FD6DBFF6E5Q82277438-65D2DC99-E308-495F-9672-38E167CE0921Q83225679-1B78D2AB-A256-465C-9E99-8045DFC0556CQ83257028-AA1F2F14-263B-4061-B947-4240BEA0BA52Q83355915-96F5D8C8-25C0-4C98-91C6-C545B7A979ECQ84306896-CD96AE8F-8243-450B-8318-7BA138790893Q84514700-83F3038F-A9DD-4B1D-A7EA-41D7AEE28616Q84758249-1FBF35CC-0578-4F5C-94E6-7A24E14E7408Q87097294-FB0830EE-CA5E-470E-8796-7B82A8A5E543Q87662085-0F809545-2B09-4495-A301-38CD516D2C77Q89012367-F035DED2-6CF0-47EF-85C2-99D7756E2DD5Q95434906-5C15237E-0756-40A3-94F8-B011C9BE9D2F
P50
description
researcher ORCID ID = 0000-0002-2118-1037
@en
wetenschapper
@nl
name
S Holding
@ast
S Holding
@es
S Holding
@nl
Stephen Holding
@en
Stephen Holding
@pl
type
label
S Holding
@ast
S Holding
@es
S Holding
@nl
Stephen Holding
@en
Stephen Holding
@pl
altLabel
S Holding
@en
prefLabel
S Holding
@ast
S Holding
@es
S Holding
@nl
Stephen Holding
@en
Stephen Holding
@pl
P1153
6701379276
P31
P496
0000-0002-2118-1037